

*Supplementary file*

*for*

## Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platform

Table S1. Solid lipid nanoparticles and nanostructured lipid carriers in clinical trials (terminated studies and studies with unknown status are excluded)

Clinical trial Identifier	Study Title	Nanocarrier	Drug	Indication	Status
NCT03823040	Clinical assessment of oxiconazole nitrate solid lipid nanoparticles loaded gel	SLNs	Oxiconazole nitrate	Tinea	Phase 1 completed
NCT04803500	Simvastatin around immediate implant	SLNs/gel	Simvastatin	Immediate implant placement Bone regeneration Alveolar bone resorption	Phase 2 completed
NCT05267899	A phase I first in human study to evaluate the safety, tolerability, and pharmacokinetics of wgi-0301 in patients with advanced solid tumors	Lipid nanoparticle suspension	WGI-0301	Advanced solid tumors	Recruiting
NCT03739931	Dose escalation study of mrna-2752 for intratumoral injection to participants in advanced malignancies	Lipid nanoparticle	mRNA-2752/ mRNA-2752+ Durvalumab	Dose escalation: relapsed/refractory solid tumor malignancies or lymphoma Dose expansion: triple negative breast cancer, hnscc, non-hodgkins, urothelial cancer, immune checkpoint refractory melanoma, and nsclc lymphoma	Recruiting
NCT04675996	First-in-human study of int-1b3 in patients with advanced solid tumors	Lipid nanoparticle	INT-1B3	Solid tumor	Recruiting
NCT05497453	A phase 1/2 study to evaluate otx-2002 in patients with hepatocellular carcinoma and other solid tumor	Lipid nanoparticle	OTX-2002/ OTX-2002 +Tyrosine kinase inhibitor One/ OTX-2002 +Tyrosine kinase	Hepatocellular carcinoma Solid tumor Hepatocellular carcinoma non-resectable Hepatocellular carcinoma recurrent Hepatocellular cancer	Recruiting

	types known for association with the MYC oncogene		inhibitor Two/ OTX-2002 + Checkpoint Inhibitor, Immune	Liver cancer Liver, cancer of, non-resectable	
		NLCs	AAHI-SC2 Vaccine/ AAHI-SC3 Vaccine/ EUA or approved vaccine	COVID-19	Recruiting
NCT05370 040	THEMBA II T-Cell Vaccine: Vaccination with saRNA COVID-19 vaccines				